52090-71-8 Usage
Uses
Used in Pharmaceutical Industry:
5-METHOXY-1H-PYRAZOLO[4,3-B]PYRIDINE is used as a synthetic prostaglandin analog for its vasodilatory and smooth muscle relaxing effects, which can be beneficial in the treatment of conditions that involve vascular constriction or muscle tension.
Used in Erectile Dysfunction Treatment:
In the field of urology, 5-METHOXY-1H-PYRAZOLO[4,3-B]PYRIDINE is used as a therapeutic agent for erectile dysfunction, leveraging its vasodilatory properties to enhance blood flow to the erectile tissues, thereby facilitating erections.
Used in Cardiovascular Disease Management:
5-METHOXY-1H-PYRAZOLO[4,3-B]PYRIDINE is utilized as a vasodilator in cardiovascular medicine to treat conditions characterized by reduced blood flow, such as angina and hypertension, by relaxing the smooth muscles of blood vessel walls and increasing blood vessel diameter.
Used as an Anti-Inflammatory Agent:
In the realm of inflammation and related conditions, 5-METHOXY-1H-PYRAZOLO[4,3-B]PYRIDINE is used for its potential anti-inflammatory properties, which may help in reducing inflammation and associated pain.
Used in Medicinal Chemistry Research:
5-METHOXY-1H-PYRAZOLO[4,3-B]PYRIDINE serves as a key compound in medicinal chemistry for the development of novel pharmaceuticals targeting prostaglandin receptors, which are involved in a variety of physiological processes and disease conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 52090-71-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,0,9 and 0 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 52090-71:
(7*5)+(6*2)+(5*0)+(4*9)+(3*0)+(2*7)+(1*1)=98
98 % 10 = 8
So 52090-71-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3O/c1-11-7-3-2-5-6(9-7)4-8-10-5/h2-4H,1H3,(H,8,10)
52090-71-8Relevant academic research and scientific papers
NEW MACROCYCLIC LRRK2 KINASE INHIBITORS
-
Page/Page column 365-366, (2021/11/13)
Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00705, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
-
Page/Page column 61; 62, (2015/03/13)
The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
